Budget 2018-19

  Long queues of vehicles could be seen in the border areas since morning as Karnataka authorities sealed many roads With the Karnataka government reinstating stricter control of transit passengers from Kerala in view of increasing Covid-19 positive cases, people here bound to Mangaluru and other parts of Dakshina Kannada for various purposes including medical needs and studies are in a fix again. Long queues of vehicles could be seen in the border areas since morning as Karnataka authorities sealed many roads including national highways and restricted entry only for those with Covid-19 negative certificates. The Dakshina Kannada authorities sealed all borders from Monday except four to cross over, sources said. According to Karnataka officials at the borders, those who wish to enter have to produce  Covid-19  negative certificate through an RT-PCR test taken 72 hours prior to their cross over time. Health and police personnel are on duty at the four borders, viz.Talapady...

  The vaccination drive will begin with 3,006 sites that will be virtually connected during the launch Prime Minister Narendra Modi will launch India’s Covid-19 vaccination programme through video at 10.30am on Saturday, the government said Thursday. The vaccination will begin with 3,006 sites that will be virtually connected during the launch. Each centre will inoculate 100 people a day to begin with. “This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers, both in government and private sectors, will receive the vaccine during this phase,” said the government. It will use Co-WIN, an online digital platform developed by Health Ministry for real-time information of vaccine stocks, storage temperature and tracking of vaccine recipients. The government faces the daunting task of rolling out shots at an accelerated pace in a country of more than 1.3 billion people which has long struggled with limited health infrastructure and...

  Data from global trials to be submitted to the Indian regulator by the end of December     The AstraZeneca-Oxford vaccine candidate has shown positive results in an interim analysis of clinical trials in the UK and Brazil, with a vaccine efficacy of up to 90 per cent in different dosing regimens. Data from the global trials would be submitted to the Indian regulator by the end of December, and Serum Institute of India (SII), AstraZeneca’s manufacturing partner here, would submit the interim data from the Indian arm by then, sources said. “It is up to the Indian regulator to decide which dosage form it would approve for the Indian population. Data from all the dosage forms will be presented before the regulator,” a source said. The recruitment for the 1,600-volunteer Indian arm of the Covishield vaccine trial is over and the trial is in the last leg. The regimen, with one half dose followed by a full dose after a month, has shown 90 per cent efficacy. This would enable m...